• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

可溶性尿激酶型纤溶酶原激活物受体作为不同临床环境中支持治疗的生物标志物。

suPAR as a biomarker of support in different clinical settings.

作者信息

Belvederi Fabio, Leggeri Simone, Urbani Andrea, Baroni Silvia

机构信息

Department of Basic Biotechnological Sciences, Intensive Care and Perioperative Clinics, Catholic University of Sacred Heart, 00168 Rome, Italy.

Department of Basic Biotechnological Sciences, Intensive Care and Perioperative Clinics, Catholic University of Sacred Heart, 00168 Rome, Italy; Unit of Chemistry, Biochemistry and Molecular Biology, "A. Gemelli" Hospital Foundation IRCCS, Largo A. Gemelli, 8, 00168 Rome, Italy.

出版信息

Clin Chim Acta. 2025 Jun 1;573:120303. doi: 10.1016/j.cca.2025.120303. Epub 2025 Apr 11.

DOI:10.1016/j.cca.2025.120303
PMID:40222544
Abstract

The urokinase-type plasminogen activator receptor (uPAR) system, which includes protease, receptor and inhibitors, is essential for key cellular functions like immune activation, cell migration, and tissue remodeling. Soluble uPAR (suPAR), released into circulation, serves as a valuable biomarker for systemic inflammation and immune activation. Elevated suPAR levels are associated with disease severity in conditions such as infections, sepsis, cardiovascular diseases, renal injury, cancer, and autoimmune diseases providing prognostic value especially in acute settings. Recent advancements in diagnostic methods, have enhanced the accuracy of suPAR measurement in serum and plasma. New rapid tests, such as suPARnostic Quick Triage, as well as turbidimetric assays, further expand its clinical applicability. In this review, we discuss the suPAR biomarker, focusing on its biochemical structure, biological functions, measurement methods and areas of clinical interest in different fields of medicine.

摘要

尿激酶型纤溶酶原激活物受体(uPAR)系统,包括蛋白酶、受体和抑制剂,对于免疫激活、细胞迁移和组织重塑等关键细胞功能至关重要。释放到循环系统中的可溶性uPAR(suPAR)是全身炎症和免疫激活的重要生物标志物。suPAR水平升高与感染、败血症、心血管疾病、肾损伤、癌症和自身免疫性疾病等病症的疾病严重程度相关,尤其在急性情况下具有预后价值。诊断方法的最新进展提高了血清和血浆中suPAR测量的准确性。新的快速检测方法,如suPARnostic快速分诊检测,以及比浊法检测,进一步扩大了其临床应用范围。在本综述中,我们讨论suPAR生物标志物,重点关注其生化结构、生物学功能、测量方法以及在不同医学领域的临床应用领域。

相似文献

1
suPAR as a biomarker of support in different clinical settings.可溶性尿激酶型纤溶酶原激活物受体作为不同临床环境中支持治疗的生物标志物。
Clin Chim Acta. 2025 Jun 1;573:120303. doi: 10.1016/j.cca.2025.120303. Epub 2025 Apr 11.
2
suPAR in cardiovascular disease.可溶性尿激酶型纤溶酶原激活物受体(suPAR)与心血管疾病。
Adv Clin Chem. 2024;121:89-131. doi: 10.1016/bs.acc.2024.04.005. Epub 2024 Apr 25.
3
Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation.可溶性尿激酶型纤溶酶原激活物受体(suPAR)作为全身性慢性炎症的生物标志物。
Front Immunol. 2021 Dec 2;12:780641. doi: 10.3389/fimmu.2021.780641. eCollection 2021.
4
Clinical relevance and cellular source of elevated soluble urokinase plasminogen activator receptor (suPAR) in acute liver failure.急性肝衰竭中可溶性尿激酶型纤溶酶原激活物受体(suPAR)升高的临床相关性及细胞来源
Liver Int. 2014 Oct;34(9):1330-9. doi: 10.1111/liv.12512. Epub 2014 Mar 19.
5
Urine soluble urokinase plasminogen activator receptor as a potential biomarker of lupus nephritis activity.尿可溶性尿激酶型纤溶酶原激活物受体作为狼疮肾炎活动的潜在生物标志物。
Biomarkers. 2021 Jul;26(5):443-449. doi: 10.1080/1354750X.2021.1910343. Epub 2021 Apr 19.
6
Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients.循环可溶性尿激酶型纤溶酶原激活物受体在重症监护病房治疗的第一周内稳定升高,并可预测危重症患者的死亡率。
Crit Care. 2011;15(1):R63. doi: 10.1186/cc10037. Epub 2011 Feb 16.
7
Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.循环可溶性尿激酶型纤溶酶原激活物在慢性肝病患者中升高,可区分肝硬化的分期和病因,并预测预后。
Liver Int. 2012 Mar;32(3):500-9. doi: 10.1111/j.1478-3231.2011.02665.x. Epub 2011 Oct 17.
8
Soluble urokinase plasminogen activator receptor (suPAR) in children with obesity or type 1 diabetes as a marker of endothelial dysfunction: a cross-sectional study.可溶性尿激酶型纤溶酶原激活物受体(suPAR)在肥胖或 1 型糖尿病儿童中作为血管内皮功能障碍的标志物:一项横断面研究。
Eur J Pediatr. 2024 May;183(5):2383-2389. doi: 10.1007/s00431-024-05496-5. Epub 2024 Mar 7.
9
Expression of Urokinase-type Plasminogen Activator Receptor and its Soluble Form in Type 2 Diabetic Kidney Disease.尿激酶型纤溶酶原激活物受体及其可溶性形式在 2 型糖尿病肾病中的表达。
Arch Med Res. 2019 Jul;50(5):249-256. doi: 10.1016/j.arcmed.2019.08.007. Epub 2019 Oct 5.
10
Urokinase plasminogen activator receptor and soluble matrix metalloproteinase-9 in acute myeloid leukemia patients: a possible relation to disease invasion.急性髓系白血病患者中的尿激酶型纤溶酶原激活物受体与可溶性基质金属蛋白酶-9:与疾病侵袭的可能关系
Hematology. 2003 Dec;8(6):385-91. doi: 10.1080/10245330310001621323.

引用本文的文献

1
Soluble Urokinase Plasminogen Activator Receptor (suPAR) Predicts 28-Day and 90-Day Mortality in Emergency Department Patients with Chest Pain, Dyspnoea, or Abdominal Pain.
Diagnostics (Basel). 2025 Nov 11;15(22):2851. doi: 10.3390/diagnostics15222851.
2
The Urokinase-Type Plasminogen Activator Receptor (uPAR) as a Mediator of Physiological and Pathological Processes: Potential Therapeutic Strategies.尿激酶型纤溶酶原激活物受体(uPAR)作为生理和病理过程的介质:潜在治疗策略
Cancers (Basel). 2025 Oct 14;17(20):3309. doi: 10.3390/cancers17203309.
3
Serum Factors in Primary Podocytopathies.
Antibodies (Basel). 2025 Sep 28;14(4):82. doi: 10.3390/antib14040082.